Published in Nat Rev Clin Oncol on August 10, 2010
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | NCT00753545
Efficacy of Letrozole in Recurrent Ovarian Cancer (MITO32) | NCT04421547
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The DNA damage response and cancer therapy. Nature (2012) 5.25
Drug development and clinical trials--the path to an approved cancer drug. Nat Rev Clin Oncol (2012) 4.98
Homologous recombination and its regulation. Nucleic Acids Res (2012) 2.44
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther (2013) 1.55
53BP1 and the LINC Complex Promote Microtubule-Dependent DSB Mobility and DNA Repair. Cell (2015) 1.29
Genomic and transcriptomic plasticity in treatment-naive ovarian cancer. Genome Res (2013) 1.15
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
The multifaceted functions of sirtuins in cancer. Nat Rev Cancer (2015) 1.04
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther (2013) 1.01
Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem (2014) 1.01
Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer (2012) 1.00
Ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells. PLoS One (2013) 0.99
MicroRNAs in cancer therapeutic response: Friend and foe. World J Clin Oncol (2014) 0.96
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies. Am J Cancer Res (2010) 0.95
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS One (2013) 0.92
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med (2014) 0.91
ATM Kinase Is Required for Telomere Elongation in Mouse and Human Cells. Cell Rep (2015) 0.85
Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Cell Cycle (2013) 0.84
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci (2013) 0.84
Small RNAs and the competing endogenous RNA network in high grade serous ovarian cancer tumor spread. Oncotarget (2016) 0.83
Update on first-line treatment of advanced ovarian carcinoma. Int J Womens Health (2013) 0.82
Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel. J Ovarian Res (2012) 0.81
Evidence for base excision repair processing of DNA interstrand crosslinks. Mutat Res (2012) 0.80
BRCA1-mediated signaling pathways in ovarian carcinogenesis. Funct Integr Genomics (2011) 0.79
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med (2016) 0.79
Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening. Ann Lab Med (2016) 0.79
BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int (2014) 0.77
Recent advances in systemic treatments for ovarian cancer. Cancer Imaging (2012) 0.76
The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels. PLoS One (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Genome maintenance mechanisms for preventing cancer. Nature (2001) 16.17
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol (2003) 8.31
Brca1 controls homology-directed DNA repair. Mol Cell (1999) 7.82
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09
BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell (2001) 6.75
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol (2003) 6.36
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
The PARP superfamily. Bioessays (2004) 6.14
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 5.81
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol (2004) 3.96
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Breast and ovarian cancer. N Engl J Med (2003) 3.84
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol (2008) 3.46
Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer (2000) 3.46
DNA recombination: the replication connection. Trends Biochem Sci (1999) 3.32
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol (2008) 3.25
Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J (2001) 3.21
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol (1991) 2.94
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst (2004) 2.72
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res (2007) 2.58
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun (1963) 2.26
Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol (2002) 2.14
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res (2009) 2.04
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol (2004) 1.89
Chromosomal translocation mechanisms at intronic alu elements in mammalian cells. Mol Cell (2005) 1.84
Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics (1946) 1.83
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol (2005) 1.67
Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. Cancer (2008) 1.66
In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics (2005) 1.62
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res (2000) 1.52
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther (2005) 1.23
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer (2007) 1.22
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer Res (1998) 1.10
Low-grade serous ovarian cancer: a unique disease. Curr Oncol Rep (2008) 1.06
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem Biophys Res Commun (2006) 1.04
BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis (2005) 1.02
PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc Biol (2008) 1.01
Inhibition of angiogenesis by the poly(ADP-ribose) polymerase inhibitor PJ-34. Int J Mol Med (2008) 0.95
Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery. BMC Cell Biol (2003) 0.93
Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol (2008) 0.87
PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol (2009) 0.86
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature (2003) 6.00
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
The DNA damage response and cancer therapy. Nature (2012) 5.25
Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer (2003) 4.96
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Stem cells and breast cancer: A field in transit. Nat Rev Cancer (2003) 3.47
Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer (2009) 3.46
Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J Cell Biol (2006) 3.24
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst (2011) 3.05
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol (2013) 2.72
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2004) 2.66
Functional and molecular characterisation of mammary side population cells. Breast Cancer Res (2002) 2.63
Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol (2005) 2.61
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov (2012) 2.53
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 2.43
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell (2008) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta (2004) 2.04
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med (2002) 1.97
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol (2010) 1.94
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
MAP kinase phosphatases. Genome Biol (2002) 1.88
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J (2003) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study. Am J Epidemiol (2014) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet (2007) 1.74
Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet (2004) 1.73
DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev (2008) 1.73
Pregnancy and the risk of breast cancer. Endocr Relat Cancer (2007) 1.72
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) (2008) 1.70
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J (2009) 1.68
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64
Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause (2011) 1.63
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov (2012) 1.62
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest (2006) 1.59
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol (2011) 1.53
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell (2010) 1.52
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep (2004) 1.52
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics (2005) 1.52
A genome-wide association study of early menopause and the combined impact of identified variants. Hum Mol Genet (2013) 1.50
Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep (2009) 1.50
Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med (2009) 1.49
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res (2009) 1.49
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med (2011) 1.48
BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res (2013) 1.47